Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + SY-5609
- Development stage
- Unknown
- Lead developer
- Syros Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Atezolizumab + SY-5609 is an investigational combination therapy comprised of **atezolizumab**, a monoclonal antibody immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1), and **SY-5609**, a highly selective and potent oral small molecule inhibitor of cyclin-dependent kinase 7 (CDK7). This combination is mechanistically rationalized for the treatment of several solid tumors, notably BRAF-mutant colorectal cancer, as CDK7 inhibition may induce DNA replication stress and immune signaling responses, enhancing susceptibility to PD-L1 blockade. The combination is being studied in phase 1/1b trials, with preclinical studies showing synergistic anti-tumor activity in molecularly-defined patient subsets[1][3][5][7].
- Other names
- atezolizumab + SY-5609atezolizumab and SY-5609 combination
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)CDK7
Beyond the preview
Go deeper on atezolizumab + SY-5609.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + SY-5609.